ReviewPharmaceuticals (Basel, Switzerland)2023
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Hyperforin as a Multifunctional Specialized Metabolite of Natural Origin for Chronic Diseases: From Molecular Mechanisms to Clinical Translation.Current issues in molecular biology · 2026Review
- Article
- Hypericin as a Photodynamic Immunomodulator: A Natural Compound for Dermatological Therapy.Drug design, development and therapy · 2026Review
- The Influence of Ethanolic Extract of Hypericum Perforatum (St. John's wort) on Growth Performance, Serum Metabolites, Fat Deposition, Immunity, and Lipid Peroxidation in Broiler Chickens.Veterinary medicine and science · 2025Article
- Antimicrobial, Anti-Biofilm Activity and Antioxidants of Phenolic Compounds Isolated FromFood science & nutrition · 2025Article
- Documentary Analysis ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Phytochemical and Toxicological Analyses of Herbal Mixtures ContainingTurkish journal of pharmaceutical sciences · 2024Article
- Potential Hepatoprotective Effects ofAntioxidants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Any defects in bile formation, secretion, or flow may give rise to cholestasis, liver fibrosis, cirrhosis, and hepatocellular carcinoma. As the pathogenesis of hepatic disorders is multifactorial, targeting parallel pathways potentially increases the outcome of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.